Catalyst Pharmaceuticals, Inc. (CPRX) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
CPRX Revenue Growth
Revenue Breakdown (FY 2025)
CPRX's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
By Geography
CPRX Revenue Analysis (2014–2025)
As of May 8, 2026, Catalyst Pharmaceuticals, Inc. (CPRX) generated trailing twelve-month (TTM) revenue of $589.0 million, reflecting solid growth of +7.6% year-over-year. The most recent quarter (Q4 2025) recorded $152.6 million in revenue, up 2.8% sequentially.
Looking at the longer-term picture, CPRX's 5-year compound annual growth rate (CAGR) stands at +37.7%, indicating outstanding long-term growth trajectory. The company achieved its highest annual revenue of $589.0 million in 2025, representing a new all-time high.
Revenue diversification analysis shows CPRX's business is primarily driven by Product Revenue Net (100%), and License And Other Revenue (0%). With over half of revenue concentrated in Product Revenue Net, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including RARE (+13.3% YoY), FOLD (+20.0% YoY), and ACAD (+9.9% YoY), CPRX has underperformed the peer group in terms of revenue growth. Compare CPRX vs RARE →
CPRX Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| CPRXCurrent | $589M | +7.6% | +37.7% | 43.8% | |
 RARE | $673M | +13.3% | +19.9% | -79.5% | |
 FOLD | $634M | +20.0% | +19.4% | 5.4% | |
 ACAD | $1.1B | +9.9% | +19.4% | 9.8% | |
 PTCT | $1.7B | -53.3% | +35.4% | 49.5% | |
 MDGL | $958M | +256.8% | - | -31.3% |
CPRX Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $589.0M | +19.8% | $501.7M | 85.2% | $257.8M | 43.8% |
| 2024 | $491.7M | +23.5% | $422.9M | 86.0% | $195.1M | 39.7% |
| 2023 | $398.2M | +85.9% | $346.2M | 86.9% | $86.8M | 21.8% |
| 2022 | $214.2M | +52.1% | $179.8M | 83.9% | $101.8M | 47.5% |
| 2021 | $140.8M | +18.3% | $118.9M | 84.5% | $52.4M | 37.2% |
| 2020 | $119.1M | +16.4% | $102.0M | 85.7% | $41.3M | 34.7% |
| 2019 | $102.3M | +20361.2% | $87.5M | 85.6% | $31.8M | 31.1% |
| 2018 | $500K | - | $-19,419,204 | -3883.8% | $-35,295,165 | -7059.0% |
| 2017 | $0 | - | $-45,689 | - | $-18,679,636 | - |
| 2016 | $0 | - | $-43,406 | - | $-19,280,201 | - |
See CPRX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CPRX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare CPRX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonCPRX — Frequently Asked Questions
Quick answers to the most common questions about buying CPRX stock.
Is CPRX's revenue growth accelerating or slowing?
CPRX maintains +7.6% revenue growth, in line with its 5-year CAGR of +37.7%. TTM revenue stands at $589M. Growth rate remains consistent with historical average.
What is CPRX's long-term revenue growth rate?
Catalyst Pharmaceuticals, Inc.'s 5-year revenue CAGR of +37.7% reflects the sustained expansion pattern. Current YoY growth of +7.6% is near this long-term average.
How is CPRX's revenue distributed by segment?
CPRX reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.